Heparan sulphate synthetic and editing enzymes in ovarian cancer

British Journal of Cancer

Volumn 96, Issue 10, 2007, Pages 1544-1548

  Backen, A C ^a   Cole, C L ^a   Lau, S C ^a   Clamp, A R ^a   McVey, R ^b   Gallagher, J T ^a   Jayson, G C ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

FGF; Heparanase; HS; HSULF 1; Ovarian cancer

Indexed keywords

CELL ENZYME; CELL SURFACE PROTEIN; ENDOSULFATASE; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; HEPARAN SULFATE; HEPARAN SULFATE SULFOTRANSFERASE 1; HEPARAN SULFATE SULFOTRANSFERASE 2; HEPARANASE; PROTEOGLYCAN; RNA; SULFATASE; SULFOTRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; CELL SURFACE; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; RNA ANALYSIS; TUMOR CELL;

CARCINOMA; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONIDASE; HEPARITIN SULFATE; HUMANS; IN SITU HYBRIDIZATION; OVARIAN NEOPLASMS; RNA, MESSENGER; SULFOTRANSFERASES;

EID: 34248573044     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603747     Document Type: Article

References (25)

1. Ai X, Do AT, Lozynska O, Kusche-Gullberg M, Lindahl U, Emerson Jr CP (2003) QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling. J Cell Biol 162(2): 341-351, doi:10.1083/jcb.200212083
2. Ai X, Do AT, Kusche-Gullberg M, Lindahl U, Lu K, Emerson Jr CP (2006) Substrate specificity and domain functions of extracellular heparan sulfate 6-O-endosulfatases, QSulf1 and QSulf2. J Biol Chem 281(8): 4969-4976, doi:10.1074/jbc.M511902200
3. Blackhall FH, Merry CL, Davies EJ, Jayson GC (2001) HS proteoglycans and cancer. Br J Cancer 85: 1094-1098, doi:10.1054/bjoc.2001.2054
4. Chang Z, Meyer K, Rapraeger AC, Friedl A. (2000) Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex in situ. FASEB J 14(1): 137 -144
5. Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, Swindell R, Slade RJ, Martin-Hirsch P, Gallagher JT, Jayson GC (2004) Distribution and clinical significance of HS proteoglycans in ovarian cancer. Clin Cancer Res 10(15): 5178-5186
6. Elkin M, Ishai-Michaeli R, Friedmann Y, Papo O, Pecker I, Voldausky I (2001) Heparanase as mediator of angiogenesis: mode of action. FASEB J 15: 1661-1663, doi: 10.1096/fj.00-0895fje
7. Gallagher JT (2001) Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest 108(3): 357-361
8. Jayson GC, Lyon M, Paraskeva C, Turnbull JE, Deakin JA, Gallagher JT (1998) HS undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J Biol Chem 273(1): 51-57
9. Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL (1993) An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 259: 1918-1921, doi: 10.1126/science.8456318
10. Kodama J, Shinyo Y, Hashen G, Hongo A, Yoshinouchi M, Hiramatsu Y (2003) Heparanase messenger RNA expression in epithelial ovarian tumor. Int J Mol Med 12(6): 961-964
11. Lai J, Chien J, Staub J, Avula R, Greene EL, Matthews TA, Smith DI, Kaufmann SH, Roberts LR, Shridhar V. (2003) Loss of HSulf-1 upregulates heparin-binding growth factor signaling in cancer. J Biol Chem 278(25): 23107-23117, doi:10.1074/jbc.M302203200
12. Lindahl U, Kusche-Gullberg M, Kjellén L (1998) Regulated diversity of HS. J Biol Chem 273: 24979-24982
13. Lyon M, Rushton G, Gallagher JT (1997) The interaction of the transforming growth factor-betas with heparin/HS is isoform-specific. J Biol Chem 272(29): 18000-18006
14. Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, Rosen SD (2002) Cloning and characterization of two extracellular heparin-degrading endosulphatases in mice and humans. J Biol Chem 277(51): 49175-49185, doi:10.1074/jbc.M205131200
15. Ornitz DM, Yayon A, Flanagan JG, Svahn CM, Levi E, Leder P (1992) Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol 12(1): 240-247
16. Ostrovsky O, Berman B, Gallagher J, Mulloy B, Fernig DG, Delehedde M, Ron D (2002) Differential effects of heparin saccharides on the formation of specific fibroblast growth factor (FGF) and FGF receptor complexes. J Biol Chem 277: 2444-2453, doi:10.1074/jbc.M108540200
17. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. (2005) Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 16(2): 159-178, doi:10.1016/j.cytogfr.2005.01.004
18. Pye DA, Vives RR, Turnbull JE, Hyde P, Gallagher JT (1998) HS oligosaccharides require 6-O-sulphation for promotion of basic fibroblast growth factor mitogenic activity. J Biol Chem 273(36): 22936-22942
19. Robinson CJ, Harmer NJ, Goodger SJ, Blundell TL, Gallagher JT. (2005) Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1.FGFR2c.heparin ternary complexes.. J Biol Chem 280(51): 42274-42282, doi:10.1074/jbc. M505720200
20. Robinson CJ, Stringer SE (2001) The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 114: 853-865
21. Simizu S, Ishida K, Osada H (2004) Heparanase as a molecular target of cancer chemotherapy. Cancer Sci 95(7): 553 -558, doi:10.1111/j.1349-7006.2004.tb02485.x
22. Viviano BL, Paine-Saunders S, Gasiunas N, Gallagher JT, Saunders S (2004) Domain-specific modification of heparan sulfate by QSULF1 modulates the binding of the bone morphogenetic protein antagonist noggin. J Biol Chem 279(7): 5604-5611, doi:10.1074/jbc.M310691200
23. Wang S, Ai X, Freeman SD, Pownall ME, Lu Q, Kessler DS, Emerson Jr CP (2004) QSulf1, a HS 6-O-endosulphatase, inhibits fibroblast growth factor signalling in mesoderm induction and angiogenesis. Proc Natl Acad Sci USA 101(14): 4833-4838, doi:10.1073/pnas.0401028101
24. Whitworth M, Backen A, Clamp A, Wilson G, McVey R, Friedl A, Rapraeger A, David G, McGown A, Slade R, Gallagher J, Jayson G (2005) Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium. Clin Cancer Res 11(12): 4282-4288
25. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM (1991) Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64(4): 841-848, doi:10.1016/0092-8674(91)90512-W.